TYRA TYRA BIOSCIENCES, INC.
- 19.440
- -0.410-2.07%
- 19.440
- 0.0000.00%
TYRA BIOSCIENCES, INC. News
TYRA BIOSCIENCES, INC.(TYRA.US) Officer Sells US$74,044.9 in Common Stock
$TYRA BIOSCIENCES, INC.(TYRA.US)$ Officer Bensen Daniel sold 3,702 shares of common stock on Jun 7, 10, 2024 at an average price of $20.0013 for a total value of $74,044.9.Source: Announcement What is
Tyra Biosciences (TYRA) Upgraded to Buy: What Does It Mean for the Stock?
Wall Street Analysts See a 27.27% Upside in Tyra Biosciences (TYRA): Can the Stock Really Move This High?
H.C. Wainwright Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Maintains Target Price $23
H.C. Wainwright analyst Mitchell Kapoor maintains $TYRA BIOSCIENCES, INC.(TYRA.US)$ with a buy rating, and maintains the target price at $23.According to TipRanks data, the analyst has a success rate
Tyra Biosciences to Present at Upcoming Investor Conferences
CARLSBAD, Calif., May 23, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target larg
Tyra Biosciences (NASDAQ:TYRA) Is In A Good Position To Deliver On Growth Plans
Just because a business does not make any money, does not mean that the stock will go down. For example, although software-as-a-service business Salesforce.com lost money for years while it grew rec
Express News | Tyra Biosciences Inc. : Oppenheimer Raises Target Price to $28 From $25
Tyra Biosciences Price Target Maintained With a $28.00/Share by Wedbush
Tyra Biosciences Price Target Maintained With a $28.00/Share by Wedbush
Express News | HC Wainwright & Co. Reiterates Buy on Tyra Biosciences, Maintains $23 Price Target
Express News | Tyra Biosciences Q1 2024 Adj EPS $(0.35) Beats $(0.46) Estimate
Express News | Tyra Biosciences Inc: Current Cash, Cash Equivalents and Marketable Securities on Hand as of Q1 Allow Co to Execute on Plans Through at Least 2026
Express News | Tyra Biosciences Inc: Tyra-300 on Track in Ach and Oncology; Surf301 Ph1 Initial Results and Ach Ind Submission Expected in 2H24
TYRA BIOSCIENCES, INC. | 10-Q: Quarterly report
Express News | Tyra Biosciences Q1 Operating Income USD -22.322 Million Vs. Ibes Estimate USD -25.9 Million
Press Release: Tyra Biosciences Reports First Quarter 2024 Financial Results and Highlights
Tyra Biosciences Reports First Quarter 2024 Financial Results and Highlights PR Newswire CARLSBAD, Calif., May 9, 2024 - TYRA-300 on track in ACH and oncology; SURF301 Ph1 initial results and ACH I
Express News | Tyra Biosciences Inc: Board Approved an Increase in Number of Authorized Directors From Nine to Ten
Press Release: Tyra Biosciences Announces Appointments of Susan Moran, M.D., M.S.C.E. and S. Michael Rothenberg, M.D., Ph.D. to Its Board of Directors
Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced changes to its Board of Directors with the appointments of Susan Moran, M.D., M.S.C.E. and S. Michael Rothenberg, M.D., Ph.D. as independent directors, and the resignation of Isan Chen, M.D. The changes are effective immediately.
Express News | Wedbush Reiterates Outperform on Tyra Biosciences, Maintains $28 Price Target
Express News | HC Wainwright & Co. Reiterates Buy on Tyra Biosciences, Raises Price Target to $23
Tyra Biosciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/20/2024 42.86% HC Wainwright & Co. $19 → $23 Reiterates Buy → Buy 12/29/2023 67.7% Wedbush $27 → $27 Re
Analysis
Price Target
No Data
